Central site photoplethysmography, medication administration, and safety

US10137245B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10137245-B2
Application numberUS-201113817156-A
CountryUS
Kind codeB2
Filing dateAug 8, 2011
Priority dateAug 17, 2010
Publication dateNov 27, 2018
Grant dateNov 27, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A monitoring and control system, apparatus and method for safe administration, reduction or cessation of administration of at least on medication, fluid or both, which includes at least one Central Source Site (CSS) Photoplethysmography (PPG) sensor coupled to means for control of delivery of the at least one medication, fluid or both.

First claim

Opening claim text (preview).

What is claimed is: 1. A system for monitoring and control for safe administration, reduction or cessation of administration of at least one of medication to a subject, comprising: (a) at least one photoplethysmography (PPG) sensor adapted to secure to a central source site of the subject; (b) an infusion pump for delivering the at least one medication to the subject, wherein the infusion pump comprises an infusion controller for increasing or decreasing flow of medication to the subject; and (c) an infusion pump agnostic safety device that is adapted to be deployed onto tubing adapted to deliver the at least one medication from the infusion pump to the subject, wherein the safety device comprises an occlusion apparatus and an occlusion controller, wherein the occlusion controller receives signals from the PPG sensor, calculates at least one respiratory parameter based on the signals from the PPG sensor, and if the at least one respiratory parameter is determined by the occlusion controller to be adverse, the occlusion controller directs the occlusion apparatus to partially or completely occlude the tubing wherein the infusion pump agnostic safety device only occludes the tubing in the event the occlusion controller determines that an adverse event has occurred. 2. The system of claim 1 , wherein the at least one respiratory parameter comprises respiratory rate, respiratory effort, or both. 3. The system of claim 1 , wherein the occlusion controller is further configured to initiate an alarm if the at least one respiratory parameter is determined by the occlusion controller to be adverse. 4. The system of claim 1 , further comprising at least one additional sensor. 5. The system of claim 4 , wherein the at least one additional sensor is selected from the group consisting of an electrocardiograph, a capnometer, a nasal pressure sensor and a nasal flow sensor. 6. The system of claim 4 , wherein the occlusion controller sends signals to the occlusion apparatus to partially or completely occlude the tubing if an adverse parameter based on signals from the at least one additional sensor is detected. 7. The system of claim 1 , wherein the infusion pump is a patient controlled anaesthesia (PCA) pump. 8. The system of claim 1 , wherein the medication comprises at least one of an opioid, a benzodiazepine and propofol. 9. The system of claim 1 , further comprising ventilation means for applying positive ventilation pressure to the subject upon receipt by the ventilation means of a control signal to initiate, increase or decrease ventilation. 10. The system of claim 9 , wherein the control signal to initiate, increase or decrease ventilation is given to the ventilation means from the occlusion controller when at least one adverse respiratory parameter is determined by the controller. 11. The system of claim 1 , wherein the central source site of the individual is the nasal septum or the nasal alar.

Assignees

Inventors

Classifications

  • Measuring pulse rate or heart rate · CPC title

  • Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition · CPC title

  • with means for measuring the humidity · CPC title

  • Sleep apnoea · CPC title

  • Head-worn items, e.g. helmets, masks, headphones or goggles · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10137245B2 cover?
A monitoring and control system, apparatus and method for safe administration, reduction or cessation of administration of at least on medication, fluid or both, which includes at least one Central Source Site (CSS) Photoplethysmography (PPG) sensor coupled to means for control of delivery of the at least one medication, fluid or both.
Who is the assignee on this patent?
Melker Richard J, Dennis Donn M, Melker Jeremy, and 5 more
What technology area does this patent fall under?
Primary CPC classification A61M5/1723. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).